Last reviewed · How we verify

NCT05699889: URICOV

Acute Kidney Dysfunction in COVID-19 and Non-COVID-19 Related ARDS

Completed Last updated 30 January 2023
What this trial tests

trial testing Data collection in COVID-19 Acute Respiratory Distress Syndrome in 130 participants. Completed in 1 September 2022.

Timeline
2 May 2020
Primary endpoint
1 September 2022
1 September 2022

Quick facts

Lead sponsorAssistance Publique Hopitaux De Marseille
StatusCompleted
Study typeOBSERVATIONAL
Enrollment130
Start date2 May 2020
Primary completion1 September 2022
Estimated completion1 September 2022
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Assistance Publique Hopitaux De Marseille — full company profile →

Who can join

18 and older, any sex, with COVID-19 Acute Respiratory Distress Syndrome or Acute Kidney Injury Due to COVID-19. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

In addition to respiratory involvement, SARS-CoV 2, the virus responsible for coronavirus 2019 or Covid-19, appears to be responsible for renal involvement such as acute renal failure or proteinuria, so the mechanisms are not known at this time. The consequences of Covid-19 on renal function in the short and long term are not known. It is important to be able to better document these renal impairments to understand the mechanisms of this disease. The main objective of this study is to describe the prevalence of Covid-19-related renal damage (acute renal failure, proteinuria, microalbuminuria, hematuria) in a large cohort of patients in intensive care for SARS-CoV 2 infection with severe respiratory impairment. The other objectives will be to evaluate in this cohort the impact of these renal impairments on the severity of the Covid-19 disease, and to compare them to the renal impairments of patients in intensive care for acute respiratory distress syndrome (ARDS) due to other respiratory diseases. Blood and urine samples will be taken at the time of intubation in all critically ill patients with respiratory distress requiring mechanical ventilation for Covid-19 or other cause of respiratory distress with PaO2/FiO2 ratio \< 300. Patients will be followed for the duration of their ICU and hospital stay. Data will be collected prospectively in three ICUs in the University Hospitals of Marseille.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Prospective Multicenter Study on Early Proximal Tubular Injury in COVID-19-Related Acute Respiratory Distress Syndrome.
    Bobot M, Heim X, Max H, Boucraut J, et al · · 2024 · cited 2× · PMID 38899195 · DOI 10.1016/j.ekir.2024.03.011
  2. Early proximal tubular injury in COVID-19 related ARDS: the URICOV study
    Bobot M, Heim X, Max H, Boucraut J, et al · · 2023 · DOI 10.21203/rs.3.rs-2656993/v1

Verify or expand the search:

Other trials of Data collection

Trials testing the same drug.

Other recruiting trials for COVID-19 Acute Respiratory Distress Syndrome

Currently open trials in the same condition.

Other Assistance Publique Hopitaux De Marseille trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05699889.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing